Opicapone is used once daily as adjunctive to levodopa/carbidopa to reduce “off” periods in patients with Parkinson’s disease.
•
In clinical trials BIPARK I and II, 50 mg of opicapone once daily was shown to be noninferior to entacapone and reduced the mean off time by about 50 min when compared to placebo.